Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P30044 (antioxidant enzyme)
 8,037 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Exogenous 17 beta-estradiol (E2) has been shown to be associated with elevated levels of erythrocyte glutathione peroxidase (GPX) activity. The purpose of this study was to examine the influence of endogenous E2, as defined by menstrual status (amenorrhea v eumenorrhea), on activity of blood antioxidant enzymes at rest and during prolonged exercise. Six amenorrheic (AMc) and six eumenorrheic (EUc) athletes were subjected to a treadmill running test at 60% VO2max for 90 minutes. Serial blood samples were taken from a forearm vein at rest, 30, 60, and 90 minutes during exercise, and 15 minutes into recovery. Resting estrogen levels were significantly lower in AMc athletes at rest and during exercise as compared with EUc athletes, whereas plasma cortisol levels in AMc were significantly higher. GPX activity was significantly higher in AMc than EUc at rest (46.9 +/- 7.7 v 30.2 +/- 2.2 nmol/min x mg Hb, P less than .05, respectively) and throughout exercise. Glutathione reductase (GR) activity was similar between the two groups at rest and was significantly higher (P less than .01) in AMc than EUc during exercise. Plasma lipid peroxidation and catalase activity did not change significantly in response to exercise, nor were they different between AMc and EUc athletes. GPX activity was found to be negatively correlated with E2 (r = -.64, P less than .01) and positively correlated with cortisol (r = .69, P less than .01). It is tentatively concluded that the alteration of hormonal status in amenorrhea has an influence on the blood antioxidant enzyme system.
 ...
PMID:Antioxidant enzyme activity during prolonged exercise in amenorrheic and eumenorrheic athletes. 198 75

Plasma levels of 17 beta-estradiol (E2) and malondialdehyde and erythrocyte antioxidant enzyme [superoxide dismutase, catalase, and glutathione-peroxidase (GSH-Px)] activities were evaluated in 20 healthy eumenorrhoic women (EW) on day 7 of the menstrual cycle and in 48 secondary hypothalamic amenorrhea patients (AP) (time 0). The AP were randomly divided into four subgroups of 12 subjects and treated with transdermal E2 for 30 days (subgroup A), oral medroxyprogesterone-acetate for 30 days (subgroup B), and transdermal E2 plus medroxyprogesterone-acetate for 30 days (subgroup C). The fourth subgroup acted as control. E2 and malondialdehyde plasma levels and superoxide dismutase, catalase, and GSH-Px activities were evaluated in subgroups A, B, and C on day 30 of therapy and in the control subgroup. GSH-Px activity was significantly higher in EW than in AP at time 0. A statistically significant increase in E2 plasma levels and GSH-Px activity was observed in subgroups A and C on day 30 of treatment, and there was a significant positive correlation between E2 plasma levels and GSH-Px activity in both subgroups. After a month of treatment, erythrocyte GSH-Px activity in subgroups A and C was not significantly different from that observed in EW. After a month of treatment, no significant variation was found in subgroup B nor in the control group. These results strongly suggest that when plasma E2 is restored to physiological levels in AP, it stimulates erythrocyte GSH-Px activity. Progesterone therapy did not induce significant modifications.
 ...
PMID:Effects of estradiol and medroxyprogesterone-acetate treatment on erythrocyte antioxidant enzyme activities and malondialdehyde plasma levels in amenorrhoic women. 898 54